Status:
COMPLETED
Ultra-high Dose Vitamin D for HSCT
Lead Sponsor:
Children's Hospital Los Angeles
Conditions:
Hematopoietic Stem Cell Transplant
Eligibility:
All Genders
Up to 25 years
Phase:
PHASE1
Brief Summary
This is a pilot study to investigate the effects of achieving adequate vitamin D levels via ultra-high-dose vitamin D supplementation given prior to hematopoietic stem cell transplant on transplant-re...
Detailed Description
Up to 70% of patients have vitamin D deficiency prior to hematopoietic stem cell transplant (HSCT). Patients with sufficient Vitamin D levels (\>50nm/L) prior to allogeneic transplant have significant...
Eligibility Criteria
Inclusion
- Patients who are preparing for HSCT
- If a patient is receiving an autologous transplant, enrollment must occur prior to first transplant in the case that the patient is planned for multiple transplants
Exclusion
- Uncorrected hypocalcemia or hypophosphatemia
- Patients in the ICU or on renal replacement therapy
- Patients who have had an allogeneic transplant within the past 12 months prior to enrollment
- Enrolled patients with 25OHD level ≤50 ng/mL continue on study
Key Trial Info
Start Date :
December 10 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 10 2020
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT03759262
Start Date
December 10 2018
End Date
May 10 2020
Last Update
May 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027